drug · unknown
rintatolimod
Phase 2updated 3mo agoby $AIM AIM ImmunoTech Inc.🔗 ChEMBL
Phase 2community read0 votes
Unknown drug with a maximum clinical stage of Phase 3 (across all indications), with 6 investigational indications.
indications
indications
Prostate Cancer
targets
Toll-like receptor 3
all catalysts(0)
nothing on the calendar yet
Trials studying rintatolimod
- phase2Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
- phase2Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
- phase2Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
- phase2Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
- —Ampligen in Chronic Fatigue Syndrome
- phase2Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
- phase2Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy
- phase2Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
News(1)
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 3mo ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that